Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
yahoo.com
finance
2022-10-18 12:11:00

Recce Pharmaceuticals

Figure 1

SARS-COV-2 50% Tissue Culture Infectious Dose (TCID50) measurement in response to treatment with R327 in Syrian golden hamsters.

Figure 2

Quantitative polymerase chain reaction (qPCR) results measuring SARS-CoV-2 genetic material in response to treatment with R327 in Syrian golden hamsters.

Highlights:

RECCE Â® 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal models

New patents lodged supporting anti-infective capability in Brazil, Canada, China, Israel, India and Vietnam

SARS-CoV-2 studies in Australia concluded following a mutual agreement



SYDNEY, Australia, Oct.
